Cell Therapy News

Cell Therapy News is an online resource dedicated to sharing the latest cell therapy, gene therapy, and regenerative medicine research.

Subscribe|Follow Us On

Kincell Bio Announces Partnership with RegCell to Advance Treg Cell Therapies into Clinical Trials for Autoimmune Diseases

February 11, 2026

[Kincell Bio] Kincell Bio announced a new collaboration with RegCell, a biotechnology company developing first‑in‑class immune tolerance platform based on epigenetically reprogrammed regulatory T cells.

First-in-Human Study Finds Novel Immune Cell Therapy Is Safe and Effective in Advanced Lymphoma

February 10, 2026

[University of Texas MD Anderson Cancer Center] In a first-in-human study, researchers at The University of Texas MD Anderson Cancer Center observed strong responses and early signs of antitumor activity in patients with difficult-to-treat non-Hodgkin lymphomas who received the novel cell therapy RB-1355.

NEO-STIM Advances Personalized Neoantigen-Specific Adoptive T Cell Therapy

February 6, 2026

[Nature Communications] Scientists reported the establishment of NEO-STIM, an ex vivo induction process to prime and expand pre-existing memory and de novo CD8+ and CD4+ T cell responses, thereby highlighting critical parameters for generating potent neoantigen-specific T cell responses.

CAR-Mediated Release of IL-10 Increases the Function of Regulatory T Cells: Relevance for Future Clinical Application

February 6, 2026

[Molecular Therapy] Researchers used their HLA-A*02 CAR and immunosuppressive IL-10 as model components to generate human CAR-Tregs that release IL-10 upon CAR-engagement.

Dysregulated Expression of the Tumor Suppressor p14ARF in Cancer Provides an Effective Target for TCR-T Cell Therapeutics

February 5, 2026

[Journal For Immunotherapy of Cancer] Scientists analyzed a panel of p16INK4A- and p14ARF-derived peptides for HLA-A*02:01-associated presentation and recognition by CD8+ T cells.

The Allogeneic FAP-CAR-IL15 iNKT Therapy MiNK-215 Remodels the Tumor Stroma to Enhance Antitumor Immunity

February 4, 2026

[Cancer Immunology Research] Researchers described the characterization of MiNK-215, an allogeneic human invariant NK T (iNKT) cell therapy in which iNKT cells were engineered to express an fibroblast activation protein (FAP)-targeting CAR and to secrete IL15 to remodel the tumor microenvironment and enhance antitumor activity.

A Universal Boosting Strategy for Adoptive T-Cell Therapy Using a Paired Vaccine/Chimeric Antigen Receptor

February 4, 2026

[Cancer Immunology Research] Scientists investigated a universal strategy for boosting transferred tumor-specific T cells for which boosting is provided through a CAR that is paired with a vaccine encoding the CAR target antigen.

CD8+ T-Cell Antitumor Immunity via Human iNKT-DC Conjugates

February 4, 2026

[Cancer Immunology Research] Investigators showed that allogeneic human CD4+ invariant NK T cells formed stably adhered bi-cellular complexes with monocyte-derived dendritic cells (DC) that migrated together as pairs and showed extended DC calcium signaling.

Tr1X Presents First Clinical Data Demonstrating Proof of Safety and Proof of Mechanism With Allogeneic Off-the-Shelf Tr1 Regulatory T Cell Therapy TRX103

February 4, 2026

[Tr1X (Businesswire)] Tr1X announced the first clinical data from its ongoing Phase I study of TRX103 in patients with hematologic malignancies undergoing HLA-mismatched hematopoietic peripheral stem cell transplantation.

Chimeric Antigen Receptor T Cells against the IGHV4-34 B Cell Receptor Specifically Eliminate Neoplastic and Autoimmune B Cells

February 4, 2026

[Science Translational Medicine] Researchers developed CAR T cells targeting the B cell receptor carrying IGHV4-34 (CART4-34). They found that CART4-34 showed specific cytotoxicity and cytokine secretion toward IGHV4-34+ malignant B cells.

Enhancing CAR- and TCR-Mediated Targeting of Cancer via an Immune Synapse-Stabilizing Receptor

February 4, 2026

[Nature Communications] In models of acute myeloid leukemia, scientists showed that a CD38-targeting synapse-stabilizing receptor boosts cytolysis of antigen-low cancer cells via a C-type lectin-like molecule-1 (CLL1)-specific CAR and a survivin-specific T cell receptor.

Dual-Antigen-Targeting T Cell Immunotherapies in MM: Circumventing Tumor Heterogeneity and Preventing Antigen Escape

February 2, 2026

[Blood] Dual-antigen targeting with T cell redirecting trispecific antibodies has demonstrated promising results in heavily pretreated multiple myeloma with several studies ongoing in earlier stages of the disease.

Published since 2002, Cell Therapy News is our longest running online publication. Our editorial team curates the top publications, reviews, and news on in vivo gene therapy, cell therapy, and immunotherapy research. With over 15,000 subscribers and followers across our website, email newsletter, and Twitter feed, we are proud to facilitate the communication of cutting-edge cell therapy innovations.